<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05103228</url>
  </required_header>
  <id_info>
    <org_study_id>52007-13/2021</org_study_id>
    <nct_id>NCT05103228</nct_id>
  </id_info>
  <brief_title>Cumulative Pregnancy Rate With Lower and Higher Gonadotropin Dose During IVF Among Poor Responders</brief_title>
  <official_title>Cumulative Pregnancy Rate With Lower and Higher Dose of Gonadotropin During Controlled Ovarian Hyperstimulation During IVF Among Expected Poor Responders: a Prospective, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter Kovacs MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaali Institute IVF Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Controlled ovarian hyperstimulation (COH) is an important step during in vitro fertilization&#xD;
      (IVF). Its aim optimally is to recruit 10-15 oocytes. When deciding on the actual treatment,&#xD;
      different stimulation protocols, various stimulating agents and wide range of gonadotropin&#xD;
      dose can one choose from. Prior to the decision on the actual stimulation protocol and&#xD;
      gonadotropin (Gn) dose the patient's expected response to stimulation is assessed primarily&#xD;
      using ovarian reserve markers. Most medications used during stimulation exert their effect in&#xD;
      a dose-dependent manner hence with a higher Gn dose one would expect a better response, more&#xD;
      oocytes. More oocytes could translate into more embryos and potentially a higher pregnancy&#xD;
      rate. The currently available evidence however does not support this practice as RCTs have&#xD;
      failed to show that the use of higher Gn dose results in higher pregnancy, live-birth rates.&#xD;
      These studies however identified patients based on different criteria, compared different&#xD;
      stimulation protocols and various Gn doses. There are only two RCTs that compared cumulative&#xD;
      live birth rates (fresh + frozen embryo transfers) and they identified poor responders based&#xD;
      on different criteria and used different drug regimens. Therefore, the aim of our study is to&#xD;
      compare cumulative IVF clinical pregnancy rates using a lower and a higher gonadotropin dose&#xD;
      among poor responders identified based on universally accepted criteria.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In vitro fertilization (IVF) is increasingly used to treat infertile couples. The first step&#xD;
      of IVF is controlled ovarian hyperstimulation (COH). During spontaneous folliculogenesis it&#xD;
      is a group (&quot;wave&quot;) of follicles that start to develop together. In a natural cycle a single&#xD;
      follicle will emerge as the dominant follicle. If, however we support follicle growth with&#xD;
      gonadotropins (Gn) we can provide support for the growth of multiple follicles. The&#xD;
      stimulation protocol and Gn dose are individually determined. The aim of personalization is&#xD;
      to avoid poor response (&lt;4 oocytes) as well as excessive response (&gt;15 oocytes). The dose of&#xD;
      Gn is determined based on ovarian reserve markers, ultrasound findings, body mass index and&#xD;
      response to previous stimulation. The two most widely used ovarian reserve markers are antral&#xD;
      follicle count (AFC) and anti-Müllerian hormone (AMH) level. Based on their value patients&#xD;
      are usually categorized as those expected to have normal response, hyper-responders and poor&#xD;
      responders. The treatment of poor responders can be challenging as they usually end up with&#xD;
      low number of oocytes no matter how we treat them. Multiple stimulation protocols and various&#xD;
      Gns have been evaluated as part of their care. Several RCTs compared the use of lower vs.&#xD;
      higher dose Gn stimulation is such cases. The rationale behind the use of higher dose Gn is&#xD;
      that in most cases gonadotropins work in a dose-dependent manner. Therefore, with the use of&#xD;
      a higher medication dose more oocytes are expected. More oocytes could translate into more&#xD;
      embryos, an improved chance for embryo selection and potentially higher pregnancy rates. Over&#xD;
      the years, poor responders have been identified based on multiple criteria. In recent years&#xD;
      attempts have been made to standardize these definitions. The two most widely accepted&#xD;
      criteria to identify poor responders are the Bologna criteria and the Poseidon&#xD;
      categorization. The Poseidon categorization takes age into consideration and describes groups&#xD;
      with an unexpected low response despite having normal ovarian reserve markers. RCTs that have&#xD;
      evaluated the effect various Gn doses among poor responders undergoing IVF have identified&#xD;
      poor responders based on different and not necessarily widely accepted criteria. In addition,&#xD;
      they compared various stimulation protocols and different Gn doses. Some studies used mild&#xD;
      stimulation while other used oral stimulating agents when the dose in international units&#xD;
      cannot be determined. Most studies have evaluated pregnancy, clinical pregnancy or live birth&#xD;
      rates in the fresh cycle only. If, however, more Gn results in more oocytes and potentially&#xD;
      more surplus embryos for cryopreservation then the cumulative pregnancy rate could be higher&#xD;
      too. This still would be a benefit that could justify the use of more medications. Two RCTs&#xD;
      evaluated cumulative pregnancy, live-birth rates. Tilborg and colleagues identified poor&#xD;
      responders based on an AFC of less than 11. They reported more oocytes and more available&#xD;
      embryos with the higher medication dose but the fresh cycle or cumulative ongoing pregnancy&#xD;
      rates were not different. Liu and colleagues identified poor responders based on the Bologna&#xD;
      criteria and compared mild stimulation (letrozole + 150 IU Gn + gonadotropin releasing&#xD;
      hormone (GnRH) antagonist) and 300 IU Gn using the GnRH agonist long protocol. They found no&#xD;
      difference in the oocyte/ embryo number or the cumulative live birth rate.&#xD;
&#xD;
      We therefore feel that the cumulative pregnancy rate (fresh + frozen embryo transfer) with&#xD;
      lower and higher dose Gn using the same stimulation protocol, among poor responder patients&#xD;
      identified based on accepted criteria has not been properly studied yet and planned this RCT&#xD;
      to find out if there is a benefit with more Gn..&#xD;
&#xD;
      We plan to recruit infertile patients between the ages of 18-42 who require IVF-ICSI&#xD;
      treatment and are identified as poor responders based on: a) AMH: 0.3-1.2 ng/ml or AFC &lt;5, b)&#xD;
      AMH&gt;1.2 ng/ml or AFC≥5 but the retrieval of ≤ 4 oocytes during previous IVF treatment.&#xD;
&#xD;
      Further inclusion criteria:&#xD;
&#xD;
      motile sperm with normal morphology obtained from the ejaculate of testicular biopsy no more&#xD;
      than 3 previous failed IVF cycles (if the patient had 2 or more previous cycles cancelled for&#xD;
      poor response she cannot be included) BMI: 18-35 kg/m2 regular 24-35 day cycles intact&#xD;
      uterine cavity&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
      presence of hydrosalpinx positive HIV, hepatitis B, C screening tests planned preimplantation&#xD;
      genetic testing of the embryos planned elective cryopreservation lack of consent not meeting&#xD;
      the inclusion criteria Eligible patients will be randomly assigned to a higher or lower Gn&#xD;
      dose treatment. In both the low and high groups two different drug regimens (follitropin&#xD;
      alpha + hp human menopausal gonadotropin or follitropin delta + hp human menopausal&#xD;
      gonadotropin) will be used. 150 IU follitropin alpha was shown to be equally effective to 10&#xD;
      mcg follitropin delta. Therefore, we expect similar response (oocyte yield) with the two&#xD;
      regimens within the high and low Gn dose groups but the study design still will allow us to&#xD;
      compare the two follitropin medications too, which is a secondary aim.&#xD;
&#xD;
      Low-dose group:&#xD;
&#xD;
        -  150 IU follitropin alpha + 75 IU highly purified human menopausal gonadotropin (hpHMG)&#xD;
&#xD;
        -  10 mcg follitropin delta + 75 IU hpHMG&#xD;
&#xD;
      High-dose group:&#xD;
&#xD;
        -  225 IU follitropin alpha + 150 IU hpHMG&#xD;
&#xD;
        -  15 mcg follitropin delta + 150 IU hpHMG The assignment to the above treatment groups&#xD;
           will enable us to compare the effect a higher and lower dose Gn among poor responders.&#xD;
           It will also allow us to compare follitropin alpha to follitropin delta (secondary aim).&#xD;
&#xD;
      The study is a multicenter study; 5 IVF centers will enroll patients. Randomization will be&#xD;
      performed according to a computer generated list. (www.randomizer.org) The planned sample&#xD;
      size is 700 patients (350 in both the low- and high-dose groups). In order to determine the&#xD;
      sample size, we calculated with a 20% pregnancy rate in a patient population that fits the&#xD;
      inclusion-exclusion criteria. We expect higher oocyte yield in the higher dose group that&#xD;
      should result in more available embryos and therefore more frozen embryo transfers. We&#xD;
      calculate that this could increase the cumulative pregnancy rate by 50%. We also believe that&#xD;
      about 20% of the patients will drop out for various reasons. Therefore, we need 350 patients&#xD;
      in both arms of the study.&#xD;
&#xD;
      After the enrollment of the first 350 patients a planned interim analysis will be performed&#xD;
      to decide whether the planned sample size is sufficient to achieve our goal. Logistic&#xD;
      regression analysis using a generalized, mixed linear model will be used to assess the impact&#xD;
      of various Gn doses on pregnancy rates. Chi-square test will be used to test significance and&#xD;
      OR will be calculated.&#xD;
&#xD;
      We will only enroll patients for whom the use of IVF-ICSI is medically indicated and who meet&#xD;
      the inclusion-exclusion criteria.&#xD;
&#xD;
      Stimulation will get started on day 2 or 3 of the menstrual cycle. During the stimulation&#xD;
      ultrasound +/- serum hormone measurements will be used to monitor response. As soon as two or&#xD;
      more follicles reach &gt;17 mm in diameter human chorionic gonadotropin (hCG) or GnRH agonist&#xD;
      trigger injection will be used and 35-36 hours later transvaginal ultrasound guided follicle&#xD;
      aspiration will be performed. The luteal phase will be supported by vaginal progesterone&#xD;
      starting on the day after the retrieval.&#xD;
&#xD;
      IVF or ICSI fertilization will be performed based on the semen parameters or previous&#xD;
      fertilization records. The day after the retrieval the success of fertilization will be&#xD;
      checked and the embryo(s) will be transferred 2-5 days after the retrieval. 12-14 days after&#xD;
      the transfer serum HCG measurement will determine whether implantation has occurred. If the&#xD;
      test is positive in 2-3 weeks a vaginal ultrasound will be done to determine the size,&#xD;
      location and number of gestational sacs. Viable pregnancies will be referred to a formal&#xD;
      prenatal care around week 8-9 of pregnancy. Delivery and perinatal outcome data will be&#xD;
      collected by phone call after the delivery.&#xD;
&#xD;
      If the fresh IVF cycle is not successful but embryos have been cryopreserved then the patient&#xD;
      will undergo a frozen embryo transfer treatment cycle either in her own cycle, or in a&#xD;
      minimally stimulated or completely artificial cycle.&#xD;
&#xD;
      The care of the patients will not differ from the care of non-study patients in terms of&#xD;
      potential medication dose, the number of clinic visits, retrieval and embryology procedures&#xD;
      as well as prenatal care.&#xD;
&#xD;
      Data will be collected for the following parameters:&#xD;
&#xD;
        -  Age&#xD;
&#xD;
        -  Cycle day 3 FSH, estradiol level&#xD;
&#xD;
        -  AMH&#xD;
&#xD;
        -  AFC&#xD;
&#xD;
        -  Indication for IVF: male, tubal, unexplained, endometriosis, diminished ovarian reserve&#xD;
&#xD;
        -  Smoking (yes-no)&#xD;
&#xD;
        -  Body mass index&#xD;
&#xD;
        -  Cycle number (fresh + frozen together)&#xD;
&#xD;
        -  Estradiol level on day 6&#xD;
&#xD;
        -  Estradiol + progesterone level at the last scan&#xD;
&#xD;
        -  Number of follicles &gt;10 mm at the end of stimulation&#xD;
&#xD;
        -  Stimulation duration&#xD;
&#xD;
        -  Endometrial thickness&#xD;
&#xD;
        -  Gn dose (daily, total)&#xD;
&#xD;
        -  Trigger mechanism (HCG vs. GnRh agonist)&#xD;
&#xD;
        -  Sperm parameters&#xD;
&#xD;
        -  Oocyte number&#xD;
&#xD;
        -  Mature (MII) oocyte number&#xD;
&#xD;
        -  Proportion of mature oocytes (MII/ oocyte number)&#xD;
&#xD;
        -  IVF vs. ICSI fertilization&#xD;
&#xD;
        -  Number of fertilized (2 pronuclei (PN)) oocytes&#xD;
&#xD;
        -  Fertilization rate per oocyte&#xD;
&#xD;
        -  Fertilization rate per mature oocyte&#xD;
&#xD;
        -  The number of good quality embryos (morphology better than 6B2 on day 3, or &gt;2BB on day&#xD;
           5) and proportion of good morphology embryos among all embryos&#xD;
&#xD;
        -  Number of transferred embryos&#xD;
&#xD;
        -  Number of cryopreserved embryos&#xD;
&#xD;
        -  Pregnancy rate (positive hCG)&#xD;
&#xD;
        -  Clinical pregnancy rate (sac with viable embryo in it)&#xD;
&#xD;
        -  Cumulative pregnancy rate (fresh + frozen embryo transfers)&#xD;
&#xD;
        -  Pregnancy/ neonatal outcome&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cumulative clinical pregnancy rate</measure>
    <time_frame>18 months</time_frame>
    <description>an ultrasound confirmation of an intrauterine gestational sac with an embryo with detectable heartbeat in it after the fresh + if available frozen emrbyo transfer treatments</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical pregnacy rate</measure>
    <time_frame>12 months</time_frame>
    <description>an ultrasound confirmation of an intrauterine gestational sac with an embryo with detectable heartbeat in it in the fresh cycle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical pregnancy rate with follitropin alpha vs. follitropin delta</measure>
    <time_frame>12 months</time_frame>
    <description>an ultrasound confirmation of an intrauterine gestational sac with an embryo with</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Infertility</condition>
  <condition>Ovarian Dysfunction</condition>
  <arm_group>
    <arm_group_label>Lower gonadotropin dose stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low-dose group:&#xD;
150 IU follitropin alpha + 75 IU highly purified human menopausal gonadotropin (hpHMG)&#xD;
10 mcg follitropin delta + 75 IU hpHMG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Higher gonadotropin dose stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-dose group:&#xD;
225 IU follitropin alpha + 150 IU ighly purified human menopausal gonadotropin (hpHMG)&#xD;
15 mcg follitropin delta + 150 IU hpHMG</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Follitropin Alfa</intervention_name>
    <description>lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)</description>
    <arm_group_label>Higher gonadotropin dose stimulation</arm_group_label>
    <arm_group_label>Lower gonadotropin dose stimulation</arm_group_label>
    <other_name>Ovaleap</other_name>
    <other_name>Bemfola</other_name>
    <other_name>Gonal F</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Follitropin delta</intervention_name>
    <description>lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)</description>
    <arm_group_label>Higher gonadotropin dose stimulation</arm_group_label>
    <arm_group_label>Lower gonadotropin dose stimulation</arm_group_label>
    <other_name>Rekovelle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>human menopausal gonadotropin</intervention_name>
    <description>lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)</description>
    <arm_group_label>Higher gonadotropin dose stimulation</arm_group_label>
    <arm_group_label>Lower gonadotropin dose stimulation</arm_group_label>
    <other_name>Menopur</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Expected poor responder based on:&#xD;
&#xD;
               1. AMH: 0.3-1.2 ng/ml or AFC &lt;5,&#xD;
&#xD;
               2. AMH&gt;1.2 ng/ml or AFC≥5 but the retrieval of ≤ 4 oocytes during previous IVF&#xD;
                  treatment.&#xD;
&#xD;
          -  motile sperm with normal morphology obtained from the ejaculate of testicular biopsy&#xD;
&#xD;
          -  no more than 3 previous failed IVF cycles (if the patient had 2 or more previous&#xD;
             cycles cancelled for poor response she cannot be included)&#xD;
&#xD;
          -  BMI: 18-35 kg/m2&#xD;
&#xD;
          -  regular 24-35 day cycles&#xD;
&#xD;
          -  intact uterine cavity&#xD;
&#xD;
          -  indication for in vitro fertilisation treatment (tubal factor, male factor, low&#xD;
             ovarian reserve, endometriosis, unexplained infertility)&#xD;
&#xD;
          -  age 18-421 yrs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  presence of hydrosalpinx&#xD;
&#xD;
          -  positive HIV, hepatitis B, C screening tests&#xD;
&#xD;
          -  planned preimplantation genetic testing of the embryos&#xD;
&#xD;
          -  planned elective cryopreservation&#xD;
&#xD;
          -  lack of consent&#xD;
&#xD;
          -  not meeting the inclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Kovacs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaali Institute IVF Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Kovacs, MD</last_name>
    <phone>+3612022802</phone>
    <email>peterkovacs1970@hotmail.com</email>
  </overall_contact>
  <results_reference>
    <citation>van der Gaast MH, Eijkemans MJ, van der Net JB, de Boer EJ, Burger CW, van Leeuwen FE, Fauser BC, Macklon NS. Optimum number of oocytes for a successful first IVF treatment cycle. Reprod Biomed Online. 2006 Oct;13(4):476-80.</citation>
    <PMID>17007663</PMID>
  </results_reference>
  <results_reference>
    <citation>Sunkara SK, Rittenberg V, Raine-Fenning N, Bhattacharya S, Zamora J, Coomarasamy A. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Hum Reprod. 2011 Jul;26(7):1768-74. doi: 10.1093/humrep/der106. Epub 2011 May 10.</citation>
    <PMID>21558332</PMID>
  </results_reference>
  <results_reference>
    <citation>Briggs R, Kovacs G, MacLachlan V, Motteram C, Baker HW. Can you ever collect too many oocytes? Hum Reprod. 2015 Jan;30(1):81-7. doi: 10.1093/humrep/deu272. Epub 2014 Oct 31.</citation>
    <PMID>25362088</PMID>
  </results_reference>
  <results_reference>
    <citation>Polyzos NP, Drakopoulos P, Parra J, Pellicer A, Santos-Ribeiro S, Tournaye H, Bosch E, Garcia-Velasco J. Cumulative live birth rates according to the number of oocytes retrieved after the first ovarian stimulation for in vitro fertilization/intracytoplasmic sperm injection: a multicenter multinational analysis including ∼15,000 women. Fertil Steril. 2018 Sep;110(4):661-670.e1. doi: 10.1016/j.fertnstert.2018.04.039.</citation>
    <PMID>30196963</PMID>
  </results_reference>
  <results_reference>
    <citation>Gougeon A. Human ovarian follicular development: from activation of resting follicles to preovulatory maturation. Ann Endocrinol (Paris). 2010 May;71(3):132-43. doi: 10.1016/j.ando.2010.02.021. Epub 2010 Apr 2. Review.</citation>
    <PMID>20362973</PMID>
  </results_reference>
  <results_reference>
    <citation>Fleming R, Broekmans F, Calhaz-Jorge C, Dracea L, Alexander H, Nyboe Andersen A, Blockeel C, Jenkins J, Lunenfeld B, Platteau P, Smitz J, de Ziegler D. Can anti-Müllerian hormone concentrations be used to determine gonadotrophin dose and treatment protocol for ovarian stimulation? Reprod Biomed Online. 2013 May;26(5):431-9. doi: 10.1016/j.rbmo.2012.02.027. Epub 2013 Feb 4. Review.</citation>
    <PMID>23507133</PMID>
  </results_reference>
  <results_reference>
    <citation>Nelson SM, Yates RW, Lyall H, Jamieson M, Traynor I, Gaudoin M, Mitchell P, Ambrose P, Fleming R. Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum Reprod. 2009 Apr;24(4):867-75. doi: 10.1093/humrep/den480. Epub 2009 Jan 10.</citation>
    <PMID>19136673</PMID>
  </results_reference>
  <results_reference>
    <citation>Nelson SM. Biomarkers of ovarian response: current and future applications. Fertil Steril. 2013 Mar 15;99(4):963-9. doi: 10.1016/j.fertnstert.2012.11.051. Epub 2013 Jan 8. Review.</citation>
    <PMID>23312225</PMID>
  </results_reference>
  <results_reference>
    <citation>La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update. 2014 Jan-Feb;20(1):124-40. doi: 10.1093/humupd/dmt037. Epub 2013 Sep 29. Review.</citation>
    <PMID>24077980</PMID>
  </results_reference>
  <results_reference>
    <citation>Practice Committee of the American Society for Reproductive Medicine. Electronic address: asrm@asrm.org; Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2020 Dec;114(6):1151-1157. doi: 10.1016/j.fertnstert.2020.09.134. Review.</citation>
    <PMID>33280722</PMID>
  </results_reference>
  <results_reference>
    <citation>Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L; ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011 Jul;26(7):1616-24. doi: 10.1093/humrep/der092. Epub 2011 Apr 19.</citation>
    <PMID>21505041</PMID>
  </results_reference>
  <results_reference>
    <citation>Poseidon Group (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number), Alviggi C, Andersen CY, Buehler K, Conforti A, De Placido G, Esteves SC, Fischer R, Galliano D, Polyzos NP, Sunkara SK, Ubaldi FM, Humaidan P. A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertil Steril. 2016 Jun;105(6):1452-3. doi: 10.1016/j.fertnstert.2016.02.005. Epub 2016 Feb 26.</citation>
    <PMID>26921622</PMID>
  </results_reference>
  <results_reference>
    <citation>Leijdekkers JA, Torrance HL, Schouten NE, van Tilborg TC, Oudshoorn SC, Mol BWJ, Eijkemans MJC, Broekmans FJM. Individualized ovarian stimulation in IVF/ICSI treatment: it is time to stop using high FSH doses in predicted low responders. Hum Reprod. 2020 Sep 1;35(9):1954-1963. doi: 10.1093/humrep/dez184.</citation>
    <PMID>31838515</PMID>
  </results_reference>
  <results_reference>
    <citation>van Tilborg TC, Torrance HL, Oudshoorn SC, Eijkemans MJC, Koks CAM, Verhoeve HR, Nap AW, Scheffer GJ, Manger AP, Schoot BC, Sluijmer AV, Verhoeff A, Groen H, Laven JSE, Mol BWJ, Broekmans FJM; OPTIMIST study group. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: The predicted poor responder. Hum Reprod. 2017 Dec 1;32(12):2496-2505. doi: 10.1093/humrep/dex318.</citation>
    <PMID>29121326</PMID>
  </results_reference>
  <results_reference>
    <citation>Liu X, Li T, Wang B, Xiao X, Liang X, Huang R. Mild stimulation protocol vs conventional controlled ovarian stimulation protocol in poor ovarian response patients: a prospective randomized controlled trial. Arch Gynecol Obstet. 2020 May;301(5):1331-1339. doi: 10.1007/s00404-020-05513-6. Epub 2020 Mar 24.</citation>
    <PMID>32211953</PMID>
  </results_reference>
  <results_reference>
    <citation>Practice Committee of the American Society for Reproductive Medicine. Electronic address: ASRM@asrm.org. Comparison of pregnancy rates for poor responders using IVF with mild ovarian stimulation versus conventional IVF: a guideline. Fertil Steril. 2018 Jun;109(6):993-999. doi: 10.1016/j.fertnstert.2018.03.019.</citation>
    <PMID>29935660</PMID>
  </results_reference>
  <results_reference>
    <citation>Arce JC, Larsson P, García-Velasco JA. Establishing the follitropin delta dose that provides a comparable ovarian response to 150 IU/day follitropin alfa. Reprod Biomed Online. 2020 Oct;41(4):616-622. doi: 10.1016/j.rbmo.2020.07.006. Epub 2020 Jul 15.</citation>
    <PMID>32819842</PMID>
  </results_reference>
  <results_reference>
    <citation>Nyboe Andersen A, Nelson SM, Fauser BC, García-Velasco JA, Klein BM, Arce JC; ESTHER-1 study group. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertil Steril. 2017 Feb;107(2):387-396.e4. doi: 10.1016/j.fertnstert.2016.10.033. Epub 2016 Nov 29.</citation>
    <PMID>27912901</PMID>
  </results_reference>
  <results_reference>
    <citation>Bosch E, Havelock J, Martin FS, Rasmussen BB, Klein BM, Mannaerts B, Arce JC; ESTHER-2 Study Group. Follitropin delta in repeated ovarian stimulation for IVF: a controlled, assessor-blind Phase 3 safety trial. Reprod Biomed Online. 2019 Feb;38(2):195-205. doi: 10.1016/j.rbmo.2018.10.012. Epub 2018 Dec 14.</citation>
    <PMID>30594482</PMID>
  </results_reference>
  <results_reference>
    <citation>Ishihara O, Klein BM, Arce JC; Japanese Follitropin Delta Phase 2 Trial Group. Randomized, assessor-blind, antimüllerian hormone-stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertil Steril. 2021 Jun;115(6):1478-1486. doi: 10.1016/j.fertnstert.2020.10.059. Epub 2020 Dec 4.</citation>
    <PMID>33272623</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 21, 2021</study_first_submitted>
  <study_first_submitted_qc>October 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Kaali Institute IVF Center</investigator_affiliation>
    <investigator_full_name>Peter Kovacs MD</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <keyword>gonadotropin</keyword>
  <keyword>follitropin aplha</keyword>
  <keyword>follitropin delta</keyword>
  <keyword>high-dose gonadotropin</keyword>
  <keyword>clinical pregnancy</keyword>
  <keyword>cumulative pregnancy rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menotropins</mesh_term>
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

